From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Rory McIlroy looks to secure career Grand Slam in 2025 at The Masters and win elusive fifth major; McIlroy will feature in ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...

Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting.

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to ...

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context.A case presentation is followed by a description of diagnostic and management ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...